Search Results
May 29, 2026, 05:23 ET Menarini Group presenta nuevos datos del estudio ELEVATE de elacestrant en combinación con capivasertib
independientemente del estado de mutación de ESR1. El estudio consta de seis regímenes de tratamiento que evalúan elacestrant en combinación con inhibidores de CDK4/6 (palbociclib, abemaciclib y ribociclib) y con inhibidores de la vía PI3K/AKT/mTOR (everolimus, alpelisib y capivasertib).Los resultados de
More news about: Menarini Industrie Farmaceutiche Riunite
May 28, 2026, 12:46 ET Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
patient outcomes, irrespective of ESR1 mutation status. The study is composed of six treatment regimens evaluating elacestrant in combination with CDK4/6 inhibitors (palbociclib, abemaciclib and ribociclib) and with inhibitors of the PI3K/AKT/mTOR pathway (everolimus, alpelisib and capivasertib).ELEVATE
More news about: Menarini Industrie Farmaceutiche Riunite
May 28, 2026, 09:00 ET ASCO Using Ryght AI's Advanced Platform to Accelerate Site Selection for Breast Cancer Clinical Trial
AI today announced a collaboration to identify and activate research sites for ASCO's clinical trial – the CDK4/6 Inhibitor Dosing Knowledge (CDK) Study – evaluating different starting doses of CDK4/6 inhibitors in patients with metastatic breast cancer. ASCO has begun using Ryght AI's platform to analyze
More news about: Ryght
May 28, 2026, 08:54 ET Florida Cancer Specialists & Research Institute Advances the Future of Cancer Care
trial.Manish R. Patel, MDA phase 1/2, first-in-human study of AVZO-021, a selective cyclin-dependent kinase 2 inhibitor (CDK2i), as monotherapy and in combination for patients with advanced solid tumors, including hormone receptor–positive (HR+)/human epidermal growth factor
More news about: Florida Cancer Specialists & Research Institute
May 26, 2026, 17:12 ET 美納里尼集團於 2026 年美國臨床腫瘤學會 (ASCO) 年會上發佈新數據
試驗，比較埃拉司群聯合依維莫司與埃拉司群聯合安慰劑，應用於患有 ER+/HER2- 晚期乳癌、帶有 ESR1 突變腫瘤並在接受內分泌治療 + CDK4/6 抑制劑*後病情惡化的患者#摘要編號：TPS1154
More news about: Menarini Industrie Farmaceutiche Riunite
May 26, 2026, 16:45 ET Menarini Group annuncia nuovi dati alla riunione annuale dell'American Society of Clinical Oncology (ASCO) 2026
pazienti con carcinoma mammario avanzato ER+/HER2- con tumori ESR1-mutati in progressione in terapia endocrina + CDK4/6i*#Abstract: TPS1154
More news about: Menarini Industrie Farmaceutiche Riunite
May 26, 2026, 09:00 ET Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
early breast cancer: a multicenter prospective studySystemic cytokine dynamics during neoadjuvant chemotherapy versus endocrine therapy and CDK4/6 inhibition in high-risk luminal breast cancer: results from the GEICAM/2019-01-CARABELA trialSession time: Monday, June 1, 2026,
More news about: Abbott
May 26, 2026, 08:10 ET Menarini Group、American Society of Clinical Oncology (ASCO)の2026年年次総会で新データを発表
二重盲検プラセボ対照無作為化第3相試験（ 内分泌療法で進行したESR1変異腫瘍を有するER+/HER2-進行がん患者 + CDK4/6i*#.が対象）要旨TPS1154
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 11:56 ET 메나리니 그룹, 2026 미국임상종양학회(ASCO) 연례회의에서 새로운 데이터 발표
욤바르트쿠삭(Antonio Llombart-Cussac)ADELA: 내분비요법 + CDK4/6 억제제 치료 후 진행한 ESR1 변이 종양 보유 ER+/HER2- 진행성 유방암 환자에서 엘라세스트란트 + 에베로리무스와 엘라세스트란트 + 위약을 비교하는 이중눈가림, 위약대조, 무작위배정 제3상 시험*#초록: TPS1154
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 09:47 ET Menarini anuncia nuevos datos en la reunión anual de la Sociedad Americana de Oncología Clínica (ASCO) 2026
ESR1 que progresan tras la terapia endocrina + CDK4/6i*#Resumen: TPS1154
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 08:13 ET Menarini Group gibt neue Daten auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO) bekannt
ER+/HER2-Patientinnen mit fortgeschrittenem Brustkrebs mit ESR1-mutierten Tumoren, die unter endokriner Therapie fortschreiten + CDK4/6i*#Zusammenfassung: TPS1154
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 08:06 ET Menarini Group annonce de nouvelles données lors de la réunion annuelle 2026 de l'American Society of Clinical Oncology (ASCO)
Patientes atteintes d'un cancer du sein avancé ER+/HER2- avec des tumeurs mutées ESR1 progressant sous traitement endocrinien + CDK4/6i*#Résumé : TPS1154
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 08:03 ET Menarini Group Anuncia Novos Dados na Reunião Anual da American Society of Clinical Oncology (ASCO) 2026
Pacientes com câncer de mama avançado ER+/HER2- com tumores com mutação ESR1 progredindo em terapia endócrina + CDK4/6i*#Resumo: TPS1154
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 07:46 ET El Grupo Menarini anuncia nuevos datos en la Reunión Anual de la Sociedad Estadounidense de Oncología Clínica (asco) 2026
ER+/HER2- pacientes con cáncer de mama avanzado con tumores con mutación ESR1 que progresan con terapia endocrina + CDK4/6i*#Resumen: TPS1154
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 06:44 ET Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
ER+/HER2- advanced breast cancer patients with ESR1-mutated tumors progressing on endocrine therapy + CDK4/6i*#Abstract: TPS1154
More news about: Menarini Industrie Farmaceutiche Riunite
May 22, 2026, 08:30 ET Caris Life Sciences to Present 32 Studies at ASCO 2026 Highlighting Advances in Multi-omic Biomarker Research and Real-World Evidence
ESR1 amplification in breast cancer, identifying it as a distinct genomic subtype associated with reduced survival and decreased benefit from CDK4/6 inhibitor therapies.The 32 studies represent collaborations with cancer centers, academic institutions and research organizations across the
More news about: Caris Life Sciences
May 21, 2026, 17:00 ET Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
program continue to differentiate Verzenio as a CDK4/6 inhibitor. In high-risk EBC, Verzenio has shown a persistent and deepening benefit beyond the two-year treatment period in the monarchE trial, an adjuvant study designed specifically to investigate a CDK4/6 inhibitor in a node-positive, high-risk EBC
More news about: Eli Lilly and Company
May 18, 2026, 07:54 ET Biotheryx Announces Data from its Phase 1 Dose Escalation Study of BTX-9341, a First-in-Class, Potent and Selective CDK4/6 Degrader, for the Treatment of Advanced/Metastatic HR+/HER2- Breast Cancer
criteria (n=10), respectively.Target engagement consistent with CDK4/6 degradation mechanism based on a significant reduction in serum Thymidine Kinase activity, and reductions in the levels of CDK4, CDK6, and CDK2 in peripheral blood mononuclear cells (PBMCs). This is consistent with BTX-9341's
More news about: Biotheryx, Inc.
May 14, 2026, 08:30 ET Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer
and D538GThe rationale for (Z)-endoxifen as a potential next-generation endocrine therapy backboneCombination strategies, including CDK4/6 inhibitor combinationsDevelopment opportunities in premenopausal breast cancer and endocrine therapy optimizationEvent DetailsDate:
More news about: Atossa Therapeutics Inc
May 12, 2026, 07:00 ET Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
(HR)-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer after at least one line of endocrine therapy + cyclin-dependent kinase (CDK) 4/6 inhibitor.*Transaction DetailsUnder the terms of the agreement, Rigel will be granted exclusive global rights to develop,
More news about: Rigel Pharmaceuticals, Inc.
May 04, 2026, 07:55 ET Biotheryx to Present Results from its Phase 1A Dose Escalation Study of BTX-9341 for the Treatment of HR+/HER2- Breast Cancer at the 2026 European Society for Medical Oncology Breast Cancer Annual Congress
of CDK4/6, important targets for a range of cancers and clinically validated in HR+/HER2- breast cancer. In preclinical breast cancer models, BTX-9341 demonstrated superiority to CDK4/6 inhibitors through potent and highly selective catalytic degradation of CDK4 and CDK6, robust inhibition of CDK2 and
More news about: Biotheryx, Inc.
Apr 27, 2026, 10:58 ET Proteotype Diagnostics Selected for EU-Funded HER-CARE Doctoral Network, Signalling Growing Research Leadership in Precision Oncology
performance in detecting early-stage (Stage I–II) breast cancer, as well as predicting and monitoring response to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i).This work expands on Proteotype's ongoing clinical research, including the UK-based
More news about: Proteotype Diagnostics
Apr 27, 2026, 10:32 ET Proteotype Diagnostics Selected for EU-Funded HER-CARE Doctoral Network, Signalling Growing Research Leadership in Precision Oncology
performance in detecting early-stage (Stage I–II) breast cancer, as well as predicting and monitoring response to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i).This work expands on Proteotype's ongoing clinical research, including the UK-based
More news about: Proteotype Diagnostics
Apr 22, 2026, 23:37 ET AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches
Board #7Abstract #: LB350CDK4 Selective Inhibitor ABK-CDK4ABK-CDK4 is a highly selective, brain-penetrant small-molecule CDK4 inhibitor developed by Abbisko Therapeutics. It is designed to selectively target CDK4, reduce CDK6-related toxicity, and expand treatment potential
More news about: Abbisko Therapeutics
Apr 07, 2026, 10:00 ET AGENTDYNAMICS ANNOUNCES DATA INTEGRATION WITH COX AUTOMOTIVE'S VINSOLUTIONS, BENEFITING DEALER CUSTOMERS
leads faster, book more appointments, and scale their BDC operations without adding headcount.AgentDynamics holds certified integrations with CDK Global and VinSolutions, with additional DMS and CRM platforms available.To learn more about AgentDynamics, visit
More news about: AgentDynamics